We are saddened to announce the passing of our good friend and colleague, Jack Snyder, on Sunday, April 24, 2022. Jack joined Summit Re in 2011 and served as regional vice president for our employer stop loss team until the time of his death. Jack will be deeply missed.
Jack’s obituary may be found at https://www.cloverdalefuneralhome.com/tributes/Jack-Snyder.
For people awaiting a transplant, expanded criteria donor (ECD) organs may bridge the gap between life and death. ECD availability can separate those on the waiting list from those who will die before receiving their needed organ.
Read moreSummit Reinsurance Services, Inc. has named Mary Sullivan to the position of vice president, sales.
Read moreOn June 7, 2021 the FDA approved Aduhelm (aducanumab) for the treatment of Alzheimer’s. The first new treatment in over 17 years, its approval has not come without controversy.
Read moreSummit Reinsurance Services, Inc. has named Scott Machut, CPA, FLMI to the position of vice president of reinsurance and provider excess sales.
Read moreSummit Reinsurance Services, Inc. has elevated Kathy Clark, RN, BSN, CMCN, to assistant vice president and director of managed care effective May 31, 2021. With this promotion, Clark assumes responsibility for Summit ReSources, Summit Re’s medical management program, and its staff.
Read moreCell and gene therapy will most certainly continue to shift paradigms for manufacturers, patients, healthcare providers and pharmacies for many years. These are groundbreaking technologies which offer hope to millions of individuals that previously had no viable options for treatment or cure.
Read moreSummit Reinsurance Services, Inc. announced a strategic collaboration with Renalogic, a solution provider offering risk management services for kidney disease. Renalogic uses a data-driven approach focused on predicting and preventing chronic conditions that lead to dialysis.
Read moreSummit Reinsurance Services, Inc. announced a strategic collaboration with AscellaHealth, a pharmacy benefit manager offering innovative specialty drug programs developed as specialized solutions to the biggest drivers of pharmacy claims.
Read moreGene and cell therapies can be life changing but come with expensive price tags. As more therapies are FDA approved, payers are looking for options to control the spiraling cost of specialty pharmacy and to project future financial risk related to new therapies coming to market.
Read more